Introduction
Acromegaly, a rare hormonal disorder caused by excessive production of growth hormone (GH) in adulthood, has witnessed significant advancements in its market dynamics. With the emergence of novel therapies and increasing awareness, the acromegaly market is poised for substantial growth by 2032. This article delves into the future prospects of the acromegaly market, focusing on FDA approvals, prevalence, clinical trials, therapies, and key companies involved in its evolution.
Current Market Landscape
According to DelveInsight's "Acromegaly Market Insights, Epidemiology, and Market Forecast-2032" report, the acromegaly market is undergoing a transformation. The United States had the largest market size in 2022, estimated at approximately USD 700 million among the seven major markets (7MM), including the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. This growth trajectory is expected to continue with a decent compound annual growth rate (CAGR) projected until 2032.
Stay ahead in acromegaly market advancements. Access the detailed 2032 forecast report now!
Key Players and Therapies
Several companies are at the forefront of developing and marketing acromegaly therapies. Notable players include Amolyt Pharma, Amryt Pharma Plc, Antisense Therapeutics Ltd, Aquestive Therapeutics Inc, ASCIL Biopharm, Camurus AB, Crinetics Pharmaceuticals Inc, Daewoong Pharmaceutical Co Ltd, Debiopharm International SA, DexTech Medical AB, Enesi Pharma Ltd, Foresee Pharmaceuticals Co Ltd, GeneScience Pharmaceuticals Co Ltd, Genevant Sciences Ltd, GlyTech Inc, Ionis Pharmaceuticals Inc, Italfarmaco SpA, OPKO Health Inc, Pharmathen Global BV, Rani Therapeutics LLC, and Strongbridge Biopharma plc.
Key therapies expected to launch in the market include Paltusotine (CRN 00808) and CAM-2029 (octreotide subcutaneous depot). Recent clinical trials have shown promising results, indicating their potential impact on the market. For instance, Crinetics Pharmaceuticals announced in March 2024 the results of a randomized, controlled, multicenter study evaluating the safety and efficacy of Paltusotine in subjects with non-pharmacologically treated acromegaly (PATHFNDR-2). Similarly, Camurus AB reported in April 2024 the outcomes of a Phase 3, open-label, single-arm, multi-center trial assessing the long-term safety of Octreotide Subcutaneous Depot (CAM2029) in patients with acromegaly.
Market Drivers and Barriers
The acromegaly market is driven by several factors, including the increasing prevalence of the disorder, advancements in diagnostic techniques, and the introduction of novel therapies. Early detection and intervention significantly improve patient outcomes and quality of life, further propelling market growth. Moreover, the demand for better technology and improved treatment practices plays a crucial role in shaping the market dynamics.
However, certain barriers exist, such as the high cost of treatment, limited awareness about the disorder, and challenges in the diagnosis due to the rarity of acromegaly. Addressing these barriers through awareness campaigns and improved healthcare infrastructure is essential for sustained market growth.
Epidemiology and Market Trends
The epidemiology section of the market report provides insights into the historical and current patient pool and forecasted trends for seven individual major countries. The prevalence of acromegaly varies, with the diagnosed patient pool expected to grow as diagnostic techniques advance. Understanding these trends is crucial for recognizing the underlying causes and addressing unmet needs.
Emerging Therapies and Pipeline Development
The uptake rate of potential acromegaly drugs recently launched or expected to be launched between 2019 and 2032 is a key area of focus. The analysis covers market uptake by drugs, patient uptake by therapies, and sales of each drug. This information helps in understanding the rapid uptake of new drugs, comparing them based on market share and size, and making informed financial and regulatory decisions.
The acromegaly pipeline includes several therapeutic candidates in Phase II and Phase III stages, with major companies proactively developing novel therapies. This pipeline development is expected to drive the acromegaly treatment markets in the upcoming years.
Market Outlook and Forecast
According to DelveInsight, the acromegaly market in the 7MM is expected to witness significant changes during the study period from 2019 to 2032. The market outlook section of the report provides a detailed comprehension of historical, current, and forecasted market trends, analyzing the impact of current therapies and unmet needs. It also evaluates the drivers, barriers, and demand for better technology, offering a thorough detail of the market trend for each marketed drug and late-stage pipeline therapy.
Discover acromegaly market trends and opportunities. Download the comprehensive 2032 forecast report.
Conclusion
The future prospects of the acromegaly market appear promising, with significant growth expected by 2032. The introduction of novel therapies, advancements in diagnostic techniques, and increasing awareness are key factors driving this growth. However, addressing barriers such as high treatment costs and limited awareness is crucial for sustained progress. With major companies actively involved in developing targeted therapeutics, the acromegaly market is set to witness transformative changes, improving patient outcomes and quality of life.
References
- DelveInsight's "Acromegaly Market Insights, Epidemiology, and Market Forecast-2032" report
- Clinical trial results and announcements from Crinetics Pharmaceuticals and Camurus AB
For more detailed information and insights, request a free sample report from DelveInsight.
List of Important Links
chronic inducible urticaria market | chronic progressive multiple sclerosis market | crohns disease cd market | defibrillators market | dermal erythema market | dysthymia market | eosinophilic asthma market | epidermolysis bullosa market | familial chylomicronemia syndrome market | healthcare competitive intelligence | Oncolytic Virus Market | Oncolytic Virus Market | Obesity Market | Business Research Services | Competitive Intelligence Services
Latest Reports Offered
Cart-related Neurotoxicity Market
DelveInsight's "CART-related Neurotoxicity Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the CART-related Neurotoxicity, historical and forecasted epidemiology as well as the CART-related Neurotoxicity market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
DelveInsight's "Crows Feet Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Crows Feet, historical and forecasted epidemiology as well as the Crows Feet market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
DelveInsight's "Herpes Simplex Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Herpes Simplex, historical and forecasted epidemiology as well as the Herpes Simplex market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
DelveInsight's "Hypercoagulability- Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Hypercoagulability, historical and forecasted epidemiology as well as the Hypercoagulability market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
.
Point Of Care Glucose Testing Market
DelveInsight’s ‘Point of Care Glucose Testing - Market Insight, Competitive Landscape and Market Forecast, 2030’ report delivers an in-depth understanding of Point of Care Glucose Testing and the historical and forecasted Point of Care Glucose Testing market trends, globally, which comprises of North America, Europe, APAC, and RoW.
DelveInsight's "Substance Drug Abuse Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Substance (Drug) Abuse, historical and forecasted epidemiology as well as the Substance (Drug) Abuse market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
DelveInsight's "Tongue Cancer Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Tongue Cancer, historical and forecasted epidemiology as well as the Tongue Cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
DelveInsight’s, “Trastuzumab Biosimilar Insight, 2024” report provides comprehensive insights about 35+ companies and 35+ marketed and pipeline drugs in Trastuzumab Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
